drugset / Trial / NCT02780180
QUantum Genomics Incremental Dosing in Heart Failure - QUID-HF
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Heart Failure (HF) a common clinical condition characterized by either by a heart that does not pump sufficiently or becomes stiff. A variety of mechanisms contribute to progressive cardiac remodeling and dysfunction. A new therapeutic approaches by preventing activation of the brain neuromodulatory pathway, may lead to improve HF. QCG001 is a prodrug of EC33, a aminopeptidase A (APA) inhibitor. QCG001 has been shown to be an antihypertensive agent in animal models. This study investigates the safety and efficacy of QGC001 in HF patients.
Timeline
- Start
- 2016-06
- Primary completion
- 2018-09-12
- Completion
- 2018-09-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Firibastat | Small molecule | 500 mg | Oral |